Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"TransThera Biosciences","sponsor":"LG Chem","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"LG Chem Life Sciences and TransThera Biosciences Ink License Agreement for Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"TransThera Biosciences"}]

TransThera Biosciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

LG Chem Life Sciences and TransThera Biosciences Ink License Agreement for Treatment of NASH

Details:

Under the terms of the agreement, LG Chem will obtain exclusive worldwide rights, except Greater China region and Japan, to develop and commercialize TT-01025.

Lead Product(s): TT-01025

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TT-01025

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: LG Chem

Deal Size: $350.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 18, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY